Effect of zafirlukast (accolate) on cellular mediators of inflammation

Bronchoalveolar lavage fluid findings after segmental antigen challenge

William Calhoun, B. J. Lavins, M. C. Minkwitz, R. Evans, G. J. Gleich, J. Cohn

Research output: Contribution to journalArticle

172 Citations (Scopus)

Abstract

The effect of zafirlukast (Z) to alter the inflammatory response to segmental antigen challenge (SAC) was assessed by bronchoalveolar lavage (BAL) in this double-blind, placebo-controlled, two-period, crossover trial in 11 allergic asthmatic patients. Patients with asthma and positive skin tests to antigen received 7 d of treatment with Z (20 mg twice daily) or placebo (P) during two trial periods 14 to 21 d apart. At steady state (Day 5), patients underwent SAC followed by BAL immedidately after challenge and 48 h later. Purified alveolar macrophages were analyzed ex vivo for phorbol myristate acetate (PMA)-driven superoxide release. Results were analyzed by analysis of variance (ANOVA). Forty-eight hours after SAC, Z therapy was associated with significantly reduced BAL lymphocytes and alcian blue- positive cells (presumably basophils) compared with P (p < 0.01), with a trend toward reduced numbers of alveolar macrophages (p = 0.06). PMA-driven superoxide release by alveolar macrophages was significantly reduced 48 h after SAC in the Z versus P arms (p <0.05. Reduction of basophil influx, mediator release, and cellular activation may be important in attenuating the late phase of asthma. Collectively, the data suggest that zafirlukast therapy alters cellular infiltration and activation associated with antigen challenge.

Original languageEnglish
Pages (from-to)1381-1389
Number of pages9
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume157
Issue number5 I
StatePublished - 1998
Externally publishedYes

Fingerprint

Inflammation Mediators
Bronchoalveolar Lavage Fluid
Antigens
Alveolar Macrophages
Bronchoalveolar Lavage
Basophils
Tetradecanoylphorbol Acetate
Superoxides
Asthma
Placebos
Alcian Blue
Skin Tests
Cross-Over Studies
zafirlukast
Analysis of Variance
Therapeutics
Lymphocytes

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Effect of zafirlukast (accolate) on cellular mediators of inflammation : Bronchoalveolar lavage fluid findings after segmental antigen challenge. / Calhoun, William; Lavins, B. J.; Minkwitz, M. C.; Evans, R.; Gleich, G. J.; Cohn, J.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 157, No. 5 I, 1998, p. 1381-1389.

Research output: Contribution to journalArticle

@article{81124d78c6d04824a451039a7cf9d5c8,
title = "Effect of zafirlukast (accolate) on cellular mediators of inflammation: Bronchoalveolar lavage fluid findings after segmental antigen challenge",
abstract = "The effect of zafirlukast (Z) to alter the inflammatory response to segmental antigen challenge (SAC) was assessed by bronchoalveolar lavage (BAL) in this double-blind, placebo-controlled, two-period, crossover trial in 11 allergic asthmatic patients. Patients with asthma and positive skin tests to antigen received 7 d of treatment with Z (20 mg twice daily) or placebo (P) during two trial periods 14 to 21 d apart. At steady state (Day 5), patients underwent SAC followed by BAL immedidately after challenge and 48 h later. Purified alveolar macrophages were analyzed ex vivo for phorbol myristate acetate (PMA)-driven superoxide release. Results were analyzed by analysis of variance (ANOVA). Forty-eight hours after SAC, Z therapy was associated with significantly reduced BAL lymphocytes and alcian blue- positive cells (presumably basophils) compared with P (p < 0.01), with a trend toward reduced numbers of alveolar macrophages (p = 0.06). PMA-driven superoxide release by alveolar macrophages was significantly reduced 48 h after SAC in the Z versus P arms (p <0.05. Reduction of basophil influx, mediator release, and cellular activation may be important in attenuating the late phase of asthma. Collectively, the data suggest that zafirlukast therapy alters cellular infiltration and activation associated with antigen challenge.",
author = "William Calhoun and Lavins, {B. J.} and Minkwitz, {M. C.} and R. Evans and Gleich, {G. J.} and J. Cohn",
year = "1998",
language = "English",
volume = "157",
pages = "1381--1389",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "5 I",

}

TY - JOUR

T1 - Effect of zafirlukast (accolate) on cellular mediators of inflammation

T2 - Bronchoalveolar lavage fluid findings after segmental antigen challenge

AU - Calhoun, William

AU - Lavins, B. J.

AU - Minkwitz, M. C.

AU - Evans, R.

AU - Gleich, G. J.

AU - Cohn, J.

PY - 1998

Y1 - 1998

N2 - The effect of zafirlukast (Z) to alter the inflammatory response to segmental antigen challenge (SAC) was assessed by bronchoalveolar lavage (BAL) in this double-blind, placebo-controlled, two-period, crossover trial in 11 allergic asthmatic patients. Patients with asthma and positive skin tests to antigen received 7 d of treatment with Z (20 mg twice daily) or placebo (P) during two trial periods 14 to 21 d apart. At steady state (Day 5), patients underwent SAC followed by BAL immedidately after challenge and 48 h later. Purified alveolar macrophages were analyzed ex vivo for phorbol myristate acetate (PMA)-driven superoxide release. Results were analyzed by analysis of variance (ANOVA). Forty-eight hours after SAC, Z therapy was associated with significantly reduced BAL lymphocytes and alcian blue- positive cells (presumably basophils) compared with P (p < 0.01), with a trend toward reduced numbers of alveolar macrophages (p = 0.06). PMA-driven superoxide release by alveolar macrophages was significantly reduced 48 h after SAC in the Z versus P arms (p <0.05. Reduction of basophil influx, mediator release, and cellular activation may be important in attenuating the late phase of asthma. Collectively, the data suggest that zafirlukast therapy alters cellular infiltration and activation associated with antigen challenge.

AB - The effect of zafirlukast (Z) to alter the inflammatory response to segmental antigen challenge (SAC) was assessed by bronchoalveolar lavage (BAL) in this double-blind, placebo-controlled, two-period, crossover trial in 11 allergic asthmatic patients. Patients with asthma and positive skin tests to antigen received 7 d of treatment with Z (20 mg twice daily) or placebo (P) during two trial periods 14 to 21 d apart. At steady state (Day 5), patients underwent SAC followed by BAL immedidately after challenge and 48 h later. Purified alveolar macrophages were analyzed ex vivo for phorbol myristate acetate (PMA)-driven superoxide release. Results were analyzed by analysis of variance (ANOVA). Forty-eight hours after SAC, Z therapy was associated with significantly reduced BAL lymphocytes and alcian blue- positive cells (presumably basophils) compared with P (p < 0.01), with a trend toward reduced numbers of alveolar macrophages (p = 0.06). PMA-driven superoxide release by alveolar macrophages was significantly reduced 48 h after SAC in the Z versus P arms (p <0.05. Reduction of basophil influx, mediator release, and cellular activation may be important in attenuating the late phase of asthma. Collectively, the data suggest that zafirlukast therapy alters cellular infiltration and activation associated with antigen challenge.

UR - http://www.scopus.com/inward/record.url?scp=0031800910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031800910&partnerID=8YFLogxK

M3 - Article

VL - 157

SP - 1381

EP - 1389

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 5 I

ER -